Lista de obras - Stephen Jolles - Dominio Público Uruguay

7th International Immunoglobulin Conference: Foreword

artículo científico publicado en 2014

A UK national audit of hereditary and acquired angioedema

artículo científico publicado en 2014

A recipient of immunoglobulin from a donor who developed vCJD

artículo científico publicado en 2009

Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts.

artículo científico publicado en 2003

Asymptomatic choroidal granulomas in common variable immunodeficiency

artículo científico publicado en 2005

Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection

artículo científico publicado en 2007

Bioavailability of IgG administered by the subcutaneous route.

artículo científico publicado en 2013

British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non‐infectious complications of Common Variable Immunodeficiency Disorders

artículo científico publicado en 2019

C1 inhibitor deficiency: 2014 United Kingdom consensus document

artículo científico publicado en 2015

Calculated globulin (CG) as a screening test for antibody deficiency

artículo científico publicado en 2014

Chronic granulomatous disease caused by mutations other than the common GT deletion in NCF1, the gene encoding the p47phox component of the phagocyte NADPH oxidase

scientific article published on 01 December 2006

Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia.

artículo científico publicado en 2015

Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.

artículo científico publicado en 2009

Clinical immunology review series: an approach to the patient with anaphylaxis.

scientific article published on July 2008

Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy.

artículo científico publicado en 2008

Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis

artículo científico publicado en 2012

Clinical uses of intravenous immunoglobulin.

artículo científico publicado en 2005

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19

artículo científico publicado en 2020

Current screening approaches for antibody deficiency

artículo científico publicado en 2015

Current strategies in TB immunotherapy.

artículo científico publicado en 2007

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

artículo científico publicado en 2015

Cytotoxic T-cell lymphoma complicating common variable immunodeficiency

artículo científico publicado en 2011

Dermatological Uses of High-Dose Intravenous Immunoglobulin ⬇️

artículo científico publicado el 1 de enero de 1998

Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

artículo científico publicado en 2011

Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency

artículo científico publicado en 2011

European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.

artículo científico publicado en 2016

European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management

artículo científico publicado en 2020

Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie

artículo científico publicado en 2017

Evaluation of a novel automated allergy microarray platform compared with three other allergy test methods.

artículo científico publicado en 2015

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.

artículo científico publicado en 2012

Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations

artículo científico publicado en 2015

Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency.

artículo científico publicado en 2015

High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders

artículo científico publicado en 2002

Immunoglobulins: current understanding and future directions

artículo científico publicado en 2014

Immunomodulatory action of intravenous immunoglobulin.

artículo científico publicado en 2002

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

article

Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis.

artículo científico publicado en 1999

Intravenous immunoglobulin and autoimmune disease

artículo científico publicado en 2007

Intravenous immunoglobulins. Current understanding and future directions.

artículo científico publicado en 2009

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials

scientific article published on 10 November 2018

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

artículo científico publicado en 2013

Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity

artículo científico publicado en 2018

Measurement of Typhim Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency.

artículo científico publicado en 2018

Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin.

artículo científico publicado en 2006

Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)

artículo científico publicado en 2014

Nuclear factor-{kappa}B is not essential for NADPH oxidase activity in neutrophils from anhidrotic ectodermal dysplasia patients.

artículo científico publicado en 2009

Patients with anaphylaxis in accident and emergency are not referred to specialised allergy services

artículo científico publicado en 2010

Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

scientific article published on 02 April 2019

Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab

artículo científico publicado en 2007

Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group.

artículo científico publicado en 2017

Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency

artículo científico publicado en 2010

Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patients

artículo científico publicado en 2011

Skin Necrosis Following Subcutaneous Immunoglobulin (SCIg).

artículo científico publicado en 2016

Subclinical infection and dosing in primary immunodeficiencies

artículo científico publicado en 2014

Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.

artículo científico publicado en 2011

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.

artículo científico publicado en 2017

The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012.

artículo científico publicado en 2014

The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017

artículo científico publicado en 2018

The evolution of cellular deficiency in GATA2 mutation

artículo científico publicado en 2013

The role of complement testing in dermatology.

artículo científico publicado en 2005

The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature.

artículo científico publicado en 2000

The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis

artículo científico publicado en 2014

The variable in common variable immunodeficiency: a disease of complex phenotypes

artículo científico

Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice

artículo científico publicado en 2005

Therapeutic strategies in common variable immunodeficiency.

artículo científico publicado en 2003

Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.

artículo científico publicado en 2005

Lista de obras de Stephen Jolles

7th International Immunoglobulin Conference: Foreword

A UK national audit of hereditary and acquired angioedema

A recipient of immunoglobulin from a donor who developed vCJD

Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts.

Asymptomatic choroidal granulomas in common variable immunodeficiency

Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection

Bioavailability of IgG administered by the subcutaneous route.

British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non‐infectious complications of Common Variable Immunodeficiency Disorders

C1 inhibitor deficiency: 2014 United Kingdom consensus document

Calculated globulin (CG) as a screening test for antibody deficiency

Chronic granulomatous disease caused by mutations other than the common GT deletion in NCF1, the gene encoding the p47phox component of the phagocyte NADPH oxidase

Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia.

Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.

Clinical immunology review series: an approach to the patient with anaphylaxis.

Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy.

Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis

Clinical uses of intravenous immunoglobulin.

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19

Current screening approaches for antibody deficiency

Current strategies in TB immunotherapy.

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Cytotoxic T-cell lymphoma complicating common variable immunodeficiency

Dermatological Uses of High-Dose Intravenous Immunoglobulin ⬇️

Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency

European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.

European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management

Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie

Evaluation of a novel automated allergy microarray platform compared with three other allergy test methods.

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.

Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations

Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency.

High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders

Immunoglobulins: current understanding and future directions

Immunomodulatory action of intravenous immunoglobulin.

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis.

Intravenous immunoglobulin and autoimmune disease

Intravenous immunoglobulins. Current understanding and future directions.

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity

Measurement of Typhim Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency.

Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin.

Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)

Nuclear factor-{kappa}B is not essential for NADPH oxidase activity in neutrophils from anhidrotic ectodermal dysplasia patients.

Patients with anaphylaxis in accident and emergency are not referred to specialised allergy services

Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab

Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group.

Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency

Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patients

Skin Necrosis Following Subcutaneous Immunoglobulin (SCIg).

Subclinical infection and dosing in primary immunodeficiencies

Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.

The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012.

The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017

The evolution of cellular deficiency in GATA2 mutation

The role of complement testing in dermatology.

The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature.

The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis

The variable in common variable immunodeficiency: a disease of complex phenotypes

Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice

Therapeutic strategies in common variable immunodeficiency.

Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.

Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project